Samsung Biologics Joins CEPI Network to Boost Pandemic Vaccine Readiness

Event summary

  • Samsung Biologics partners with CEPI to strengthen outbreak-ready vaccine production, joining CEPI's Vaccine Manufacturing Facility Network (VMFN).
  • Initial budget of up to $20 million to establish scalable, rapid manufacturing process for recombinant-protein vaccines.
  • Samsung Biologics to conduct simulated outbreak response exercise using wild-type H5 influenza as a prototype pathogen.
  • Commitment to provide up to 50 million vaccine doses and one billion doses of drug substance for future pandemic situations.

The big picture

This collaboration aligns with CEPI's 100 Days Mission to develop vaccines within 100 days of identifying a novel pathogen, enhancing the global response to future epidemic and pandemic threats. By integrating Samsung Biologics' advanced manufacturing capabilities into CEPI's VMFN, the partnership aims to ensure equitable access to vaccines, particularly in Low- and Middle-Income Countries (LMICs). The strategic move broadens the technological mix and geographical reach of the VMFN, reinforcing a more agile and distributed supply chain for future health threats.

What we're watching

Execution Risk
Whether Samsung Biologics can successfully demonstrate the speed and robustness of its end-to-end capabilities during the simulated outbreak response exercise.
Regulatory Dynamics
The pace at which the generic regulatory submission dossier can be prepared and approved for rapid deployment during future outbreaks.
Market Positioning
How this partnership will affect Samsung Biologics' competitive standing in the global vaccine manufacturing landscape.

Related topics

Partnership